BIO — BIO-RAD LABORATORIES, INC.

—
NYSE · Unknown · Unknown · CIK 12208 ·
Last close
$377.69
Market Cap
$8.19B
52W High
$396.23
52W Low
$236.73
ADV30
269,459
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 651,000,000 345,800,000 72,600,000 371,400,000 10,252,000,000 517,000,000 3,078,100,000
Mar 2026 592,100,000 309,400,000 34,100,000 -527,100,000 9,790,000,000 507,200,000 2,938,700,000
Dec 2025 693,200,000 345,200,000 53,900,000 720,000,000 10,576,500,000 529,800,000 3,122,900,000
Sep 2025 653,000,000 343,400,000 63,900,000 -341,900,000 9,696,400,000 395,800,000 2,959,600,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$492,600,000
Investing CF
$-237,100,000
Financing CF
$-120,800,000
CapEx
$-139,500,000
Dividends Paid
—
Buybacks
$-132,700,000
EPS Diluted TTM
$8.25
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$8,020,600,000
Inventory
$780,600,000
Receivables
$441,800,000
ST Investments
$1,101,500,000
EBIT TTM
$399,200,000
Pretax Income TTM
$350,400,000
Interest Exp TTM
$48,800,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,589,299,968
EBITDA
$441,000,000
Free Cash Flow
$283,187,488
Enterprise Value
$9,626,843,136
Total Cash
$1,618,499,968
Total Debt
$1,370,400,000
Shares Out
21,677,137
Trailing EPS
$8.20
Book Value
$268.30
ROE
3.1%
ROA
1.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,583,200,000 218,600,000 759,900,000 10,576,500,000 3,122,900,000 7,453,600,000 532,200,000
Dec 2024 2,566,500,000 269,000,000 -1,844,200,000 9,364,100,000 2,794,800,000 6,569,300,000 455,200,000
Dec 2023 2,671,200,000 337,800,000 -637,300,000 12,299,100,000 3,557,900,000 8,741,200,000 374,900,000
Dec 2022 2,802,200,000 475,100,000 -3,627,500,000 13,501,666,000 3,886,414,000 9,615,252,000 194,400,000

TTM Snapshot

Revenues TTM
$2,470,200,000
NetIncome TTM
$1,434,400,000
OpCashFlow TTM
$0
Assets (Latest)
$10,576,500,000
Forward EPS
$10.03

Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $390.00 · spot: $377.69 · call volume: 305 · put volume: 10
Expected Move to 2026-10-16: ±$20.10 (5.32%) — implied range $357.59 – $397.79 · ATM straddle on $380.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MTLPF Metlen Energy & Metals PLC/ADR $8.16B $57.30 —
KTOS KRATOS DEFENSE & SECURITY SOLUTIONS, INC. $8.27B $44.07 —
MLSPF Melrose Industries Plc/ADR $8.06B $6.47 —
SPIWF SPIE SA/ADR $8.33B $49.30 —
SPIIY SPIE SA/ADR $8.37B $12.38 —

News headlines (Yahoo Finance, 1h cache)

Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
2026-09-26 03:02 · Yahoo
Cell Isolation/Cell Separation Market Forecasts Growth from $6.97B (2026) to $13.51B by 2032, Profiling Thermo Fisher, Bio-Rad, Beckman Coulter & Sartorius
2026-09-24 13:00 · Yahoo
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
2026-09-24 10:34 · Yahoo
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
2026-09-16 13:00 · Yahoo
Bio Rad (BIO) Stock Could Be 23% Overvalued As Column Expansion Continues
2026-09-15 00:20 · Yahoo
Transcriptome Sequencing Market - Global Forecast to 2035; Bulk RNA-Seq Maintains Its Technology Market Lead
2026-09-10 11:03 · Yahoo
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
2026-09-03 15:30 · Yahoo
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
2026-08-31 13:00 · Yahoo
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
2026-08-20 15:23 · Yahoo
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?
2026-08-14 00:13 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.